Published in Gene Therapy Weekly, December 4th, 2003
von Hofe was director of programs & operations, discovery research at Millennium Pharmaceuticals. There he presided over technology development projects, which contributed to bringing in about $75 million per year in technology transfer projects with Monsanto and Aventis.
Previously, von Hofe was director, new targets at Hybridon, Inc., where he coordinated in-house and collaborative research that critically validated gene targets for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.